Introduction and Aim
====================

Obesity and ectopic fat accumulation are the fundamental pathogenic conditions in patients with type 2 diabetes mellitus (T2DM), and they are ultimately associated with insulin resistance^[@bib1],\ [@bib2])^. Practical approaches designed to reduce body weight and fat mass (especially ectopic fat accumulation) may have additional therapeutic benefits in preventing and treating T2DM^[@bib2],\ [@bib3])^. Previous reports have indicated that administration of a sodium-glucose co-transporter 2 inhibitor (SGLT2i) improves glycemic control and reduces body weight, fat mass, and adipose tissue volume (subcutaneous and visceral)^[@bib4]--[@bib6])^. The systematic review demonstrated that treatment with dapagliflozin (a SGLT2i that is widely used in clinical practice) combined with metformin is associated with the significant additional benefit of weight loss compared with other oral glucose-lowering agents^[@bib7])^.

Dapagliflozin exerts its glucose-lowering effects through inhibition of the SGLT2 protein in the kidney proximal tubule, resulting in the excretion of glucose and calories into the urine^[@bib8])^. This negative energy balance results in dapagliflozin treatment-associated weight loss, as has been demonstrated in several clinical studies^[@bib9]--[@bib11])^. Diabetic patients frequently exhibit a progressive decline in muscle mass and impaired muscle functional quality^[@bib3])^, which are caused by reduced insulin sensitivity and decreased mitochondrial function due to underlining pathogenesis of T2DM^[@bib12])^. Regarding SGLT2i-induced weight reduction, clinical concern has been raised over the occurrence of sarcopenia (decrease in muscle mass)^[@bib13],\ [@bib14])^, and clinical studies are therefore needed to determine the weight loss efficacy and any effects on muscle mass of dapagliflozin treatment in T2DM patients^[@bib15])^.

We hypothesized that dapagliflozin treatment would improve glycemic control and reduce body weight and total fat mass without reducing muscle mass. Thus, we investigated the effects of dapagliflozin on total and skeletal muscle mass, muscle fat content and muscle quality in uncontrolled (hemoglobin A1c \[HbA1c\] \> 7%) T2DM patients.

Materials and Methods
=====================

1.. Study Population and Study Protocol
---------------------------------------

We prospectively recruited stable but uncontrolled (HbA1c \> 7%) Japanese T2DM patients, who had a body mass index (BMI) \> 35 kg/m^2^ and who were not taking SGLT2i medicines, from the Diabetes Care Center in the Jinnouchi Hospital between 2014 and 2016. Exclusion criteria were the following: type 1 DM; ketoacidosis; age \> 80 years; unstable cardiovascular disease; active inflammation; severe liver disease; dementia; chronic kidney disease (estimated glomerular filtration rate \< 45 mL/min/1.73 m^2^); urinary tract infection; cancer; and those who could not remain standing to have a body composition examination. Patients with newly-diagnosed diabetes without any treatment were also excluded. Attending physicians at the Jinnouchi Hospital non-randomly separated the enrolled patients into two groups, i.e., dapagliflozin group and non-SGLT2i group. The decision of treatment arm was left to the physicians\' discretion. Patients in the dapagliflozin group were treated with their ongoing treatments and additional dapagliflozin (5 mg/day) for 6 months. Patients in the non-SGLT2i group were treated with their ongoing treatments and an intensification of glucose-lowering medications (increased doses and new medications) without SGLT2i for 6 months to reduce HbA1c to \< 7.0% by the end of the study period. Before starting the treatments, a fasting blood sample was collected from the antecubital vein in the morning and body composition (fat and muscle mass) was measured by bioelectrical impedance analysis using InBody770 (Biospace, Seoul, Korea) and plain abdominal computed tomography (CT; Aquilion CXL, Toshiba, Tokyo, Japan). After six months of treatment, another fasting blood sample was collected and a second body composition analysis using InBody and plain abdominal CT was performed. The primary outcome was dapagliflozin-induced changes in muscle mass as assessed by bioelectrical impedance analysis and CT analysis as a prospective parallel-arm open-label study. The secondary outcome was dapagliflozin-induced changes in muscle fat content as assessed by CT radiation attenuation. This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Human Ethics Review Committee of the Jinnouchi Hospital and a signed consent form was obtained from each patient.

2.. Outcomes
------------

The primary end point was treatment-induced changes in skeletal muscle mass as assessed by bioelectrical impedance analysis using InBody770. We tested the non-inferiority of the dapagliflozin-induced changes in skeletal muscle mass compared with non-SGLT2i therapy following a six-month course of treatment.

3.. Measurement of Body Composition
-----------------------------------

Body composition including total fat mass, soft lean mass, and skeletal muscle mass was measured using a direct segmental multi-frequency bioelectrical impedance analyzer (InBody770)^[@bib16])^. This analyzer processes 30 impedance measurements using six different frequencies (1, 5, 50, 250, 500, 1,000 kHz) on five body segments (right arm, left arm, trunk, right leg, left leg), and 15 reactance measurements using tetrapolar 8-point tactile electrodes at three different frequencies (5, 50, 250 kHz) on the same five body segments^[@bib17])^. The skeletal muscle mass index (SMI), a quantitative indicator of sarcopenia, was calculated using the following formula: SMI= (skeletal muscle mass \[kg\]/the square of height \[m^2^\])^[@bib18])^.

4.. Measurement of Psoas Muscle Area at the Third Lumbar Vertebral Body
-----------------------------------------------------------------------

We manually traced the outer margin of the cross-section of the major psoas muscle at the level of the caudal end of the third lumbar vertebral body (L3) on the plain abdominal CT images, and defined the sum of the left and right cross-sectional areas of psoas muscles as the psoas muscle area (PMA) (cm^2^). The psoas muscle index (PMI), a quantitative index of the total skeletal muscle mass, was calculated using the following formula: PMI=(PMA \[cm^2^\]/the square of the height \[m^2^\])^[@bib19])^.

5.. Measurement of CT Radiation Attenuation in the Lumbar Paraspinal Muscles at L3
----------------------------------------------------------------------------------

To assess skeletal muscle quality including fatty muscle (ectopic fat deposition in muscle), we traced the lumbar paraspinal muscles at the level of the L3 and measured the CT radiation attenuation of the traced area by calculating the average Hounsfield unit values^[@bib20])^.

6.. Blood Sampling and Measurement of Clinical Parameters
---------------------------------------------------------

Fasting blood samples were collected from the antecubital vein in the morning. Blood analyses were conducted in the hospital laboratory for the measurement of blood glucose, HbA1c, and creatinine.

7.. Statistical Analysis
------------------------

The results of normally distributed continuous variables (determined by the Shapiro-Wilk test) are expressed as the mean ± standard deviation (SD), and those of continuous variables with skewed distributions are expressed as median (interquartile range). Differences in the baseline characteristics of the two groups were analyzed by Student\'s *t*-test, Mann-Whitney *U*-test, or Fisher\'s exact test for categorical data, as appropriate. Paired Student\'s *t*-test or Wilcoxon test was used to analyze the effect of each treatment. Pearson\'s correlation coefficient was used to investigate the association between changes in body fat percentage and changes in total body weight. The choice of a non-inferiority margin and standard SD for changes in skeletal muscle mass was based on a combination of clinical judgment and statistical reasoning. Because there are no data from previous trials to help define the clinical difference between treatments, we relied on our own and outside experts\' clinical judgment to determine that a margin of inferiority of 1 kg is an irrelevant small difference and the SD for changes in skeletal muscle mass is 1 kg. Non-inferiority was demonstrated within a margin of 1 kg at a one-sided significance level of 0.025 and a power of 80% (calculated when changes in skeletal muscle mass in both arms are the same and the SD for changes in skeletal muscle mass is 1 kg), with a sample size of 17 per arm (34 in total). Including loss to follow up and variations in numbers between the two treatment groups, we set a sample size of 50 in total. The difference between treatment groups in changes in skeletal muscle mass from baseline to six months was also assessed using analysis of covariance with adjustment for the baseline measures as covariates. We calculated the inter-group difference with a 95% confidence interval (CI) for the primary end point to examine the non-inferiority. A *p*-value \< 0.05 was considered statistically significant. Statistical analyses were performed using the Statistical Package for Social Sciences version 23 (SPSS Inc., IBM, Tokyo, Japan).

Results
=======

1.. Baseline Clinical Characteristics of the Study Subjects
-----------------------------------------------------------

The present study involved 50 Japanese patients with stable but uncontrolled (HbA1c \> 7.0%) T2DM. The clinical baseline characteristics of the patients are shown in **[Table 1](#T1){ref-type="table"}**. The mean age of the 50 patients was 56.1 years, 72.0% were male, the mean BMI was 27.1 kg/m^2^, HbA1c was 7.9%, and fasting plasma glucose (FPG) was 138 mg/dL. There were no significant differences in the measured characteristics between groups. At enrollment, 36% of patients were treated with insulin. The baseline characteristics of patients in the dapagliflozin group were similar to those of the non-SGLT2i group. BMI, HbA1c, FPG, and duration of diabetes were not significantly different between groups. None of the baseline parameters, except waist circumference (*p* \< 0.05) and total fat mass (*p* \< 0.05), were significantly different between the dapagliflozin and non-SGLT2i-groups (**[Table 2](#T2){ref-type="table"}**).

###### Baseline Clinical Characteristics

                                    Total patients     Dapagliflozin      Non SGLT2i         *p* value
  --------------------------------- ------------------ ------------------ ------------------ ------------
  Age (years)                       56.1 ± 7.6         55.6 ± 7.4         56.7 ± 7.9         *p* = 0.60
  Sex (male:%)                      72.0%              75.0%              68.2%              *p* = 0.75
  Body mass index (kg/m^2^)         27.1 ± 2.9         27.5 ± 2.4         26.2 ± 3.4         *p* = 0.12
  Hypertension                      68.0%              67.9%              68.2%              *p* = 1.00
  Dyslipidemia                      74.0%              75.0%              72.7%              *p* = 1.00
  Current smoking                   28.0%              28.6%              27.3%              *p* = 1.00
  Duration of diabetes (years)      10.0 (8.0--17.3)   10.0 (7.3--16.5)   10.5 (8.8--19.3)   *p* = 0.31
  Hemoglobin A1c (%)                7.7 (7.3--8.2)     7.9 (7.3--8.7)     7.6 (7.2--8.1)     *p* = 0.47
  Fasting plasma glucose (mg/dL)    138 ± 37           137 ± 38           139 ± 35           *p* = 0.83
  Anti-diabetic medicines (%)       --                 --                 --                 --
      Sulfonylureas                 34.0%              39.3%              27.3%              *p* = 0.55
      Glinide                       14.0%              14.3%              13.6%              *p* = 1.00
      Metformin                     100%               100%               100%               NA
          Daily dose (mg/day)       1060.0 ± 376.5     1116.1 ± 322.6     988.6 ± 432.9      *p* = 0.26
      Alpha-glucosidase inhibitor   14.0%              10.7%              18.2%              *p* = 0.68
      Thiazolidinedione             8.0%               14.3%              0.0%               *p* = 0.12
      DPP-4 inhibitor               44.0%              39.3%              50.0%              *p* = 0.57
      GLP-1 receptor agonist        8.0%               10.7%              4.5%               *p* = 0.62
      Insulin                       36.0%              28.6%              45.5%              *p* = 0.25

NA: not available, SGLT2i: sodium glucose co-transporter 2 inhibitor, DPP-4: dipeptidyl peptidase, GLP-1: glucagon like peptide-1

###### Changes in Body Weight, Body Composition, and Glucose Metabolic Parameters

                                         Dapagliflozin (*n* = 28)                     *P* value                        Non-SGLT2i (*n* = 22)   *P* value                               
  -------------------------------------- -------------------------------------------- -------------------------------- ----------------------- ------------------- ------------------- -------------
  HbA1c (%)                              7.9 (7.3--8.7)                               6.8 (6.4--7.5)                   *p* \< 0.01             7.6 (7.2--8.1)      7.0 (6.6--7.7)      *p* \< 0.01
  Absolute change (%)                    −1.2 (−1.4−−0.5)                                                              −0.6 (−1.0−−0.3)                                                
  Fasting plasma glucose (mg/dl)         137 ± 38                                     116 ± 24                         *p* \< 0.01             139 ± 35            127 ± 27            *p* \< 0.18
  Absolute change (mg/dl)                −20.5 ± 27.3                                                                  −12.4 ± 42.0                                                    
  Body mass index (kg/m^2^)              27.5 ± 2.4                                   26.3 ± 2.5                       *p* \< 0.01             26.2 ± 3.4          25.8 ± 3.6          *p* \< 0.03
  Absolute change (kg/m^2^)              −1.2 ± 0.9                                   [†](#tf1){ref-type="table-fn"}   −0.4 ± 0.8                                                      
  Body weight (kg)                       76.7 ± 7.4                                   73.3 ± 7.5                       *p* \< 0.01             71.6 ± 10.3         70.6 ± 10.8         *p* \< 0.03
  Absolute change (kg)                   −3.4 ± 2.6                                   [†](#tf1){ref-type="table-fn"}   −1.1 ± 2.0                                                      
  Waist circumference (cm)               96.7 ± 6.6^[‡](#tf2){ref-type="table-fn"}^   92.9 ± 7.4                       *p* \< 0.01             92.5 ± 7.4          91.0 ± 8.2          *p* \< 0.06
  Absolute change (cm)                   −2.8 (−6.6−−0.8)                                                              −1.3 (−3.7−1.7)                                                 
  Total Fat mass (kg)                    24.9 ± 6.0^[‡](#tf2){ref-type="table-fn"}^   21.8 ± 6.6                       *p* \< 0.01             21.3 ± 6.1          20.7 ± 6.8          *p* \< 0.20
  Absolute change (kg)                   −3.1 ± 2.6                                   [†](#tf1){ref-type="table-fn"}   −0.6 ± 2.0                                                      
  Body Fat Percentage (%)                32.3 ± 7.3                                   29.6 ± 8.2                       *p* \< 0.01             29.6 ± 7.4          29.0 ± 8.0          *p* \< 0.26
  Absolute change (%)                    −2.7 ± 2.9                                   [†](#tf1){ref-type="table-fn"}   −0.5 ± 2.2                                                      
  Soft lean mass (kg)                    49.1 ± 6.3                                   48.6 ± 6.8                       *p* = 0.18              47.6 ± 7.9          47.1 ± 7.8          *p* = 0.12
  Absolute change (kg)                   −0.5 ± 1.8                                                                    −0.5 ± 1.3                                                      
  Soft lean mass percentage (%)          64.1 ± 6.8                                   66.4 ± 7.8                       *p* \< 0.01             66.6 ± 7.1          67.1 ± 7.6          *p* \< 0.25
  Absolute change (%)                    2.4 ± 2.6                                    [†](#tf1){ref-type="table-fn"}   0.5 ± 2.1                                                       
  Skeletal muscle mass (kg)              28.7 ± 4.0                                   28.5 ± 4.3                       *p* = 0.34              27.8 ± 5.0          27.5 ± 4.9          *p* = 0.15
  Absolute change (kg)                   −0.2 ± 1.2                                                                    −0.2 ± 0.7                                                      
  Skeletal muscle mass percentage (%)    37.5 ± 4.3                                   38.9 ± 5.0                       *p* \< 0.01             38.8 ± 4.4          39.2 ± 4.7          *p* \< 0.18
  Absolute change (%)                    1.5 ± 1.7                                    [‡](#tf2){ref-type="table-fn"}   0.4 ± 1.2                                                       
  Psoas muscle area Index (cm^2^/m^2^)   6.46 ± 1.82                                  6.39 ± 1.80                      *p* = 0.13              6.56 ± 1.92         6.48 ± 1.88         *p* = 0.10
  Absolute change (cm^2^/m^2^)           −0.071 (−0.214−0.087)                                                         0.000 (−0.121−0.000)                                            
  Paraspinal muscle attenuation (HU)     43.6 (38.7--48.5)                            45.1 (38.9--50.6)                *p* \< 0.01             43.6 (39.6--46.9)   43.1 (37.5--47.7)   *p* \< 0.86
  Absolute change (HU)                   1.61 ± 2.32                                  [‡](#tf2){ref-type="table-fn"}   0.10 ± 2.3                                                      

HbA1c, hemoglobin A1c,

*p* \< 0.01,

*p* \< 0.05 Dapagliflozin group versus Non-SGLT2 inhibitor group at baseline and absolute change

2.. Changes in HbA1c, FPG, and Body Weight
------------------------------------------

All patients in the dapagliflozin group were administered 5 mg of dapagliflozin per day. In the non-SGLT2i group, the dosage of previously prescribed medications including insulin was increased in 86.4% of patients (insulin: *n* = 6; metformin: *n* = 5; sulfonylurea: *n* = 5; dipeptidyl peptidase-4 inhibitor: *n* = 1), and new medications were additionally administered to 22.7% of patients (sulfonylurea: *n* = 3; alpha-glucosidase inhibitor: *n* = 3; glinide: *n* = 1; dipeptidyl peptidase-4 inhibitor: *n* = 1). All 50 patients presented with significant improvements in HbA1c (median \[interquartile range\]; pre-treatment 7.7% \[7.3--8.2\] vs. post-treatment 6.9% \[6.5--7.5\], *p* \< 0.01), FPG (mean ± SD; pre-treatment 138 ± 37 vs. post-treatment 121 ± 26 mg/dL, *p* \< 0.01), and BMI (pre-treatment 27.1 ± 2.9 vs. post-treatment 26.5 ± 2.9 kg/m^2^, *p* \< 0.01). HbA1c, body weight, and BMI were significantly decreased in both groups and the decreases in HbA1c and FPG were not significantly different between the dapagliflozin and non-SGLT2i groups (**[Table 2](#T2){ref-type="table"}**).

3.. Changes in Body Composition (Soft Lean Mass, Skeletal Muscle Mass, Fat Mass, and SMI)
-----------------------------------------------------------------------------------------

Dapagliflozin treatment for six months significantly decreased body weight, total fat mass, and body fat percentage. Changes in body fat percentage were significantly correlated with changes in body weight (all subjects: *r* = 0.788, *p* \< 0.001). Both treatments produced non-significant modest reductions in soft lean mass (**[Fig. 1](#F1){ref-type="fig"}**) and skeletal muscle mass (**[Fig. 2](#F2){ref-type="fig"}**) from baseline to month six (**[Table 2](#T2){ref-type="table"}**). The absolute change in soft lean mass and skeletal muscle mass was not significantly different between the two groups. SMI as an indicator of sarcopenia did not significantly decrease after treatment with dapagliflozin or non-SGLT2i therapy (dapagliflozin group: pre-treatment 10.24 ± 0.92 vs. post-treatment 10.16 ± 1.02 kg/m^2^, *p* = 0.30; non-SGLT2i group: pre-treatment 10.07 ± 1.20 vs. post-treatment 9.99 ± 1.16 kg/m^2^, *p* = 0.17), and the absolute change in SMI was comparable between the two groups (dapagliflozin group −0.08 ± 0.41 kg/m^2^ vs. non-SGLT2i group −0.08 ± 0.27 kg/m^2^, *p* = 1.00). In the analysis of covariance model using the baseline measures as covariates, the dapagliflozin group demonstrated a non-significant change in skeletal muscle mass compared with the non-SGLT2i group (*p* = 0.951). An inter-group comparison of change in skeletal muscle mass demonstrated non-inferiority of dapagliflozin therapy against non-SGLT2i therapy (group difference: 0.0 kg, 95% CI: −0.6 to 0.6 kg).

![Dot plot of soft lean mass before and after 6 months of dapagliflozin or non-sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy as measured using a bioelectrical impedance analyzer\
Soft lean mass of each patient before and after each therapy presented as a dot plot, with black circles and bars representing the mean and standard error of the mean, respectively.](jat-25-467-g001){#F1}

![Dot plot of skeletal muscle mass before and after 6 months of dapagliflozin or non-sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy as measured using a bioelectrical impedance analyzer\
Skeletal muscle mass of each patient before and after each therapy presented as a dot plot, with black circles and bars representing the mean and standard error of the mean, respectively.](jat-25-467-g002){#F2}

4.. Changes in PMI
------------------

Dapagliflozin treatment for six months did not significantly decrease PMI as assessed by CT imaging analysis (**[Table 2](#T2){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}**). The absolute change in PMI was not significantly different between the dapagliflozin and non-SGLT2i groups (**[Table 2](#T2){ref-type="table"}**). PMI was significantly correlated with SMI in the present study population (*r* = 0.61, *p* \< 0.001).

![Dot plot of the psoas muscle index before and after 6 months of dapagliflozin or non-sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy as assessed by abdominal computed tomography\
Psoas muscle index of each patient before and after each therapy presented as a dot plot, with black circles and bars representing the mean and standard error of the mean, respectively.](jat-25-467-g003){#F3}

5.. Changes in Radiation Attenuation of the Third Lumbar Paraspinal Muscles
---------------------------------------------------------------------------

Dapagliflozin therapy produced a significant increase in CT radiation attenuation in the third lumbar paraspinal muscles while non-SGLT2i therapy did not (**[Table 2](#T2){ref-type="table"}**). The absolute change in CT radiation attenuation in the lumbar paraspinal muscles was significantly greater in the dapagliflozin group than in the non-SGLT2i group (**[Table 2](#T2){ref-type="table"}**, *p* = 0.03).

6.. Sub-Group Analysis in Non-Obese Patients
--------------------------------------------

We performed sub-group analysis for the 44 non-obese (BMI \< 30 kg/m^2^) patients (BMI 26.3 ± 2.5 kg/m^2^; dapagliflozin group, *n* = 24; non-SGLT2i group, *n* = 20). This sub-group analysis showed that dapagliflozin therapy did not significantly decrease soft lean mass, skeletal muscle mass, or PMI (soft lean mass: pre-treatment 49.4 ± 6.4 vs. post-treatment 49.0 ± 7.0 kg, *p* = 0.41; skeletal muscle mass: pre-treatment 28.9 ± 4.1 vs. post-treatment 28.8 ± 4.5 kg, *p* = 0.67; PMI: pre-treatment 6.87 ± 2.17 vs. post-treatment 6.80 ± 2.2 cm^2^/m^2^, *p* = 0.21). There were also no significant differences in change in soft lean mass, skeletal muscle mass, SMI, or PMI between the dapagliflozin and non-SGLT2i groups (data not shown).

Discussion
==========

The present study demonstrated that treatment with dapagliflozin for six months significantly improved glycemic control and reduced body weight and total fat mass without affecting muscle mass in Japanese T2DM patients. Interestingly, dapagliflozin therapy also produced a significant increase in CT-attenuation in the third lumbar paraspinal muscles, indicative of a reduction in ectopic fat in skeletal muscle. These results will help to provide the practical usefulness of dapagliflozin for T2DM patients.

T2DM patients frequently exhibit increased ectopic fat accumulation^[@bib2])^ and a progressive decline in muscle mass and quality (so-called fatty and deteriorated muscles)^[@bib3])^, which might play an important role in the pathogenesis of impaired glucose metabolism^[@bib21])^. Thus, a bidirectional therapeutic approach to reduce body weight by decreasing fat mass and preserving or increasing muscle mass is desired^[@bib1])^. Body weight reduction by SGLT2i treatment is reported to be mainly the result of fat mass reduction^[@bib4])^. In a 102-week clinical trial, the dapagliflozin-induced reduction in fat mass was significantly greater than that of the placebo, while the decrease in lean mass was comparable between groups^[@bib9])^. An important finding of the present study is the confirmation that the weight loss by dapagliflozin in T2DM patients is primarily the result of a reduction in fat mass rather than in soft lean mass. We found that total fat mass was significantly decreased following dapagliflozin treatment, but soft lean mass, skeletal muscle mass, SMI and PMI were not significantly reduced. Conversely, Bouchi *et al.* recently demonstrated that luseogliflozin treatment significantly decreased SMI in patients with T2DM^[@bib14])^. In the present study, patients in the non-SGLT2i therapy group did not increase body weight, even though insulin was frequently increased or added to their ongoing anti-diabetic medications. Explaining the results obtained using the present study protocol might enhance patients\' treatment motivation leading to reductions in body weight similar to those of the previous studies^[@bib4],\ [@bib9])^. Body weight reduction with loss of fat mass from taking anti-diabetic medications might positively affect patients\' quality of life, treatment satisfaction, and motivation for the continuation of anti-diabetic therapy^[@bib22])^; thus dapagliflozin may be a clinically useful therapeutic strategy for overweight and obese T2DM patients.

Loss of body muscle mass is an important component of sarcopenia, leading to frailty and mortality^[@bib3])^. Regarding SGLT2i-induced weight reduction, sarcopenia has been raised as a clinical concern for animal models^[@bib23])^ and clinical situations^[@bib13],\ [@bib14])^. Here we demonstrate that in the dapagliflozin group, total muscle mass and skeletal muscle were not significantly decreased and body percentage of skeletal muscle (skeletal muscle mass × 100/total body weight) significantly increased. These results contrast with our primary concern of the sarcopenic side effects from SGLT2i treatment. It is generally accepted that SGLT2i-induced osmotic diuresis is responsible for the initial phase (within three months) body weight decline^[@bib24])^, while the long-term reduction in body weight is due to loss of fat mass^[@bib25])^. Hirose *et al.* reported that eight weeks of tofogliflozin administration reduced the body weight and fat-free mass without affecting the total fat mass in Japanese patients with T2DM^[@bib26])^, indicating that body water loss might be the main factor responsible for weight loss in the early phase of SGLT2i-therapy. A previous clinical investigation showed that subjects compensated for SGLT2i-induced negative energy balance by increasing their calorie intake, leading to limited catabolism^[@bib27])^. This instinctive eating response against SGLT2i-induced continuous caloric loss could prevent a decrease in muscle mass. However, SGLT2i-induced stimulation of energy intake and excessive appetite could also offset the beneficial effects of SGLT2i on weight reduction and fat loss^[@bib27])^; thus, adequate dietetic therapy is clinically important to gain the full benefits of SGLT2i treatment.

SGLT2is induce gluconeogenesis, lipolysis, and increase glucagon levels^[@bib23],\ [@bib28])^, which may also contribute to reduction of body fat mass. Interestingly, regarding skeletal muscle quality, we found that six months of dapagliflozin treatment decreased the accumulated ectopic fat content in paraspinal muscles, as assessed by CT radiation attenuation. Previously, Komiya *et al.* indicated that lower CT radiation attenuation in the paraspinal muscles was significantly related to a poor insulin secretion response and worsened glycemic control in patients with overweight and obesity^[@bib29])^. It has been demonstrated that short-term dapagliflozin treatment effectively improves muscle insulin sensitivity in T2DM patients, indicative of beneficial effects of SGLT2i on skeletal muscle function and quality^[@bib28])^. Recently, Sano *et al.* reported that SGLT2i treatment significantly increased hand-grip strength^[@bib30])^. Taken together, these results suggest that SGLT2i therapy has the potential to improve muscle quality and function while preserving muscle mass.

In contrast with previous clinical studies on Caucasian T2DM patients^[@bib7],\ [@bib31])^, the Japanese T2DM patients from the present study typically had a BMI of less than 30 kg/m^2^(overweight but not obese). In our subgroup analysis of non-obese subjects (BMI \< 30 kg/m^2^), dapagliflozin did not significantly reduce muscle mass during the clinical course of SGLT2i-induced weight loss. However, we only included a few patients with normal body weight (BMI \< 25 kg/m^2^or BMI \< 23 kg/m^2^for Japanese as risk of diabetes^[@bib32])^) in the present study, thus we cannot confirm the sarcopenic safety of dapagliflozin in patients with adequate or lower body weight.

Our study had several limitations, including the small number of subjects involved, the non-random allocation, open-label design, and relatively short study period. The BMI and frequency of thiazolidinedione prescriptions in the dapagliflozin group were higher than those in the non-SGLT2i group, suggestive of patient selection bias. More detailed and longer studies are needed to validate the effects of SGLT2i treatment on muscle mass and muscle fat content demonstrated in the present study. This study included uncontrolled T2DM patients (HbA1c \> 7.0%) only, and included few older patients and normal weight patients. Further studies evaluating the effects of dapagliflozin on muscle mass and quality should be considered in T2DM patients of older age, normal weight, and with well-controlled diabetes. The mechanisms of dapagliflozin-induced weight and fat loss and muscle mass preservation could not be determined in the present study. We did not collect objective or quantitative data on daily diet or exercise therapy (aerobic and resistance training) in the patients\' treatment logs. Control of food, protein, amino acid, fluid intake, daily measurement of exercise intensity, and 24-h quantification of urinary glucose excretion could help to elucidate the underlying mechanisms.

Conclusion
==========

Treatment with dapagliflozin for six months significantly improved glycemic control and reduced body weight without reducing total or skeletal muscle mass in T2DM patients. Regarding the balance between fat muscle mass, dapagliflozin is promising as a new agent for the treatment of T2DM.
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